ABSTRACT Metachromatic leukodystrophy is a hereditary neurodegenerative disorder in man associated with deficient arylsulfatase-A activity (aryl-sulfate sulfohydrolase, EC 3.1.6.1). The same enzyme deficiency has been noted in clinically normal individuals, a condition known as pseudo arylsulfatase-A deficiency. With a nonselective method, somatic cell hybrids were obtained from cultured fibroblasts of these two types of individuals; the hybrids showed no restoration of arylsulfatase-A activity. Thus, metachromatic leukodystrophy and pseudo arylsulfatase-A deficiency are allelic conditions. Although these conditions cannot be distinguished by simple quantitative arylsulfatase-A activity assays, they can be differentiated with sucrose density gradient centrifugation, Cellogel electrophoresis, or isoelectric focusing in polyacrylamide gels. In each case, a small amount of .activity with characteristics of arylsulfatase-A was found only from fibroblasts of pseudo arylsulfatase-A-deficient individuals and not from those of metachromatic leukodystrophy-patients. This residual enzyme has the same pH optimum, heat stability, inhibitor sensitivity, and Km as the normal enzyme but slightly different isoelectric points. In conclusion, although pseudo arylsulfatase-A deficiency and metachromatic leukodystrophy have very different clinical outcomes, they are due to. mutations of the same structural gene, coding for arylsulfatase-A. These two conditions can be differentiated now by simple electrophoretic analysis of the residual arylsulfatase-A activity.
aryl.sulfate sulfohydrolase,. EC 3.1.6.1) in metachromatic leukodystrophy (MLD) (5) . The demonstration that these enzyme activities are deficient in serum, leukocytes, or fibroblasts constitutes the biochemical confirmation of the diseases. Prenatal diagnoses of affected fetuses have been made successfully, based on the finding of deficient. enzyme activities in the cultured amniotic cells (6) . In recent years, however, normal individuals have been recognized who have similar enzyme deficiencies but do not manifest any of the stigmata of the clinical syndromes-i.e., deficiencies of hexosaminidases A and B (7) , hexosaminidase A (8, 9) , f-galactosidase (10), a-fucosidase (11) , and ARSA (12) . In these cases, simple enzyme assays cannot distinguish between the clinically affected and their normal counterparts, thus creating a dilemma in-the biochemical diagnosis of these conditions.
This paradoxical situation is clearly demonstrated in MLD. It is a severe neurodegenerative disease associated with deficient ARSA activity and inherited as an autosomal recessive trait.
Since 1975, individuals have been identified, through population screening or from members of a family with an affected individual, as having severely reduced ARSA activity as in MLD patients. However, they did not suffer from any of the neuropathy typical of MLD (12) (13) (14) (15) . This is now referred to as the pseudo arylsulfatase-A deficiency (PD) condition (16) .
Although both PD and MLD cell homogenates had drastically reduced ARSA activity, regardless of whether artificial or natural substrates were used (13, 15) , the intact PD cultured fibroblasts appeared able to degrade exogenous radioactively labeled cerebroside sulfatide, the natural substrate for ARSA (16) . In contrast, intact cells from MLD patients were severely impaired in such degradative activity. This sulfatide-loading technique to differentiate between MLD and PD was used successfully for prenatal diagnosis in afamily in which both types of individuals occurred (16) . However, recent evidence has shown that, under some culture conditions, it may not distinguish unequivocally a PD from an MLD condition (17) .
Although the biochemical basis for the ARSA deficiency in healthy individuals is not understood, many hypotheses have been raised to explain the genetic relationship between MLD and PD (18) (19) (20) . The basic question is whether these conditions are due to mutations in the same or different genes. The answer is provided here by complementation studies. Somatic cell hybrids were isolated with a nonselective technique from fused cultured cells of PD individuals and MLD patients and examined for restoration of ARSA activity. If PD and MLD are due to mutations in different genes, ARSA activity would be restored in -their hybrids by intergenic complementation. In contrast, if they are allelic mutations, complementation would not be expected.
We also report here that fibroblasts from PD individuals possess a distinct amount of ARSA that is not found in those of MLD patients. This residual ARSA was detectable by various analytical techniques on the bases of molecular weight or charge differences and was compared to the normal enzyme in several biochemical characteristics.
MATERIALS AND METHODS Cell Culture. Normal fibroblasts were established from skin biopsy samples of individuals without any known metabolic disease. Those from a patient with the infantile form of MLD were supplied by H. L. Nadler (Wayne State University, Detroit, MI). The PD fibroblasts were supplied by H. Kihara (UCLA School of Medicine, CA). They were established from an individual who was clinically normal but had ARSA activity in the same range as MLD patients and was the father of a child with MLD.
Abbreviations: PD, pseudo arylsulfatase-A deficiency; MLD, metachromatic leukodystrophy; ARSA, arylsulfatase-A; PGM, phosphoglucomutase.
The publication costs-of this article were defrayed in part bypage charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 (24) and identified with karyotyping in situ (25) and phosphoglucomutase (PGM) isozyme analysis (26, 27) .
ARSA Assays. The quantitative assay with. the artificial substrate 4-methylumbelliferyl sulfate.was based on the principle that ARSA is selectively inhibited by silver ions while arylsulfatase-B, another soluble sulfatase also active towards the same substrate, is not (28) . The complete procedure was described by Chang et al. (29) .
The quantitative assay with radioactively labeled natural sub- (31) .
Isoelectric focusing of ARSA was performed according to published methods (32) , either with narrow range (pH 4-7) or wide range (pH 4.5-10.0) Ampholines (LKB) in polyacrylamide (5.0% acrylamide/0.2% bisacrylamide) tube gels (5 X 115 mm). Each gel was focused at 0.5 mA for 0.5 hr and then at 1 mA until the voltage reached 1,000 V (in about 3 hr). Focusing continued at constant voltage for a total of 4.5 hr. The gels were then rinsed in 0.5 M acetate buffer, pH 5.6, incubated with 3 mg of 4-methylumbelliferyl sulfate per ml of 0.5 M acetate buffer, pH 5.6, for 15 min on ice in the dark, drained, and further incubated at 37C in a dark moist chamber for 0.5-1 hr. Photographs with Polaroid type 51 film were taken without further enhancement of the fluorescence by alkaline buffers so as to reduce diffusion.
Density Gradient Sedimentation. ARSA and arylsulfatase-B were separated by their different sedimentation velocities in a sucrose density gradient according to the method of Martin and Ames (33) . Three-drop fractions were collected from the bottom of the gradient, adjusted with acetic acid to pH 5.6, and assayed for total arylsulfatase activity with 4-methylumbelliferyl sulfate as the substrate.
Enzymatic Characterization. The residual ARSA in PD was analyzed for its Km, pH optimum, and heat stability as described in ref. 25 . The temperature at which 50% of the activity remained after 10 min (t5o) was calculated with linear regression from the logarithmically transformed data according to the method described by Feinstein et al. (34) . For the silver inhibition studies, fibroblast extracts were subjected to the wide-range isoelectric focusing to separate the ARSA from arylsulfatase B. The ARSA activity in the gel was assayed in the presence or absence of silver ions according to the procedure described by Chang et al. (35) .
Protein was determined by the method of Lowry et al. with bovine serum albumin as the standard (36) . All clones were judged to be putative tetraploids on account of their larger interphase nuclei and wider metaphase plates (37) . Only 211. clones were sufficiently vigorous in growth for karyotyping in-situ; 48% were confirmed to be tetraploids, while the rest were mixed diploid and tetraploid (37%) and pure diploid (15%). Extracts from all the tetraploid clones were then subjected to Cellogel-electrophoresis and their PGM1 isozyme patterns were examined to identify their parental origins; the MLD parental strain was PGM12 and the PD strain was PGM1 1. It was recognized at this point that, for unknown reasons, the Hepes/minimal essential medium used to maintain these clones interfered with the PGM1 electrophoretic separation so that the parental origins of the clones could not be established unequivocally. In Thus, 28 tetraploid clones were shown to be from PD cell selffusion (i.e., they were PGM1 1), 13 were from MLD cell selffusion (i.e., they were PGM1 2), and 11 were from heterologous fusion between the MLD and PD parental strains (i.e., they were PGM1 2-1).
All tetraploid clones were screened for ARSA activity with Cellogel electrophoresis (Fig. 1) incided with the normal peak of ARSA, which has a molecular weight of about 128,000. No activity peak from the MLD cells was detected in this sedimentation position (Fig. 2) .
To verify that the residual ARSA peak in PD cells ws active towards the natural substrate, the following experiment was performed. Extracts from normal, PD, and MLD cells were subjected to sucrose-gradient sedimentation. Their ARSA peak fractions (22 and 23) were assayed with cerebroside [3S]sulfatide. The activity of the fractions from the normal cell extract was 35-51 nmol/hr per ml and that of the PD extract was 2.0-2.6 nmol/hr per ml. Those from the MLD extract had 1.0-1.4 nmol/hr per ml, which was not significantly above the background. Hence, a low but definite activity towards the natural substrate was obtained in the ARSA peak from the PD cells.
The isoelectric points of the residual ARSA from PD cells were ascertained by focusing in polyacrylamide gel with narrow-range (pH 4-7) Ampholine (Fig. 3) (18) (19) (20) . First, PD is due to a dominant mutation at a-locus separate from that of MLD. Second, PD is due to mutation of a gene whose product affects the. expression of ARSA activity-for example, an activator protein. Both hypotheses require-a defective PD locus that is separate from the structural gene coding for ARSA. Because MLD is due to mutation of the ARSA structural gene (38) , one would expect that, if these hypotheses were correct, intergenic complementation of the ARSA locus between MLD and PD would occur; that was not what we observed. In contrast, according to the third hypothesis, there are at least three alleles at the ARSA structural gene locus, normal, MLD, and PD. In this case, MLD and PD would be allelic genes so that their somatic cell hybrids would not be expected to demonstrate intergenic complementation.
In this study, somatic cell hybrid clones from MLD and PD fibroblasts failed to restore ARSA activity, as shown by quantitative assay of ARSA activity (Table 1) and qualitative analysis by Cellogel electrophoresis (Fig. 1) . The lack of complementation of ARSA activity is, therefore, compatible only with the third hypothesis (19) .
The genotypes of the MLD and PD may be interpreted as follows: The MLD condition is the result of homozygosity of the MLD/MLD alleles at the structural gene locus. Since the PD fibroblasts were obtained from the father of an MLD child, PD is the result of the genotype MLD/PD. This is the same inheritance pattern as in the third hypothesis, proposed by Langenbeck et al. (19) on the basis of only family pedigree and biochemical phenotypes.
This genotype also accounts for what initially appeared to be an anomalous result in our hybrid clones. In the diploid parental cell types, the MLD cells were completely deficient in anodic activity corresponding to ARSA. The PD parent, however, had a faint anodic band of ARSA activity. One would expect to see this faint activity band retained in the hybrid clones even in the absence of complementation. Instead, a total-deficiency similar to that of the MLD cells was observed. Two possibilities may account for this. First, MLD was a dominant condition so that in the hybrids, the MLD genome continues to suppress the expression of any ARSA activity. This is untenable because MLD is known to be recessively inherited in man and, even in hybrid genomes constructed from normal and MLD somatic cells, ARSA activity is not suppressed (21) .
The second possibility is as follows. ARSA from normal fibroblasts has a molecular weight of about 128,000 (Fig. 2) . Under denaturing conditions, it can be dissociated into subunits of molecular weight 60,500 (39) . Therefore, it may be assumed that ARSA consists of two polypeptide subunits. If each allele makes a subunit of ARSA, in the PD condition with a genotype of MLD/PD, pd and. mld subunits will be made. .The variety of composition of ARSA in the PD individual will be distributed as (pd + mld)2 = pd2 + 2pdmld + mld2. Since mld2 is the same inactive molecule found in the MLD homozygote, and the pd-mld combination is likely to be inactive, the only active structure will be the pd2, which thus accounts for 1/4 of the total moieties of ARSA in the PD individual. However, in the PD-MLD hybrids, the total genomic composition of the ARSA locus is PD/MLD + MLD/MLD. The possible combinations of ARSA become (pd + 3mld)2 = pd2 + 6pdmld + 9mld2. The only partially active moiety, pd2, is now greatly reduced from 1/4 to 1/16 of the total ARSA molecules, thus accounting for the absence of detectable ARSA activity bands in the hybrid clones.
Biochemical Basis of the. PD Condition. When the residual ARSA activity was compared between samples from PD and MLD individuals, the PD values were consistently slightly higher than those of the MLD (12) (13) (14) (15) . This was true whether natural or artificial substrates were used. It is known that the residual activity assayable in crude MLD extracts is attributed to nonspecific crossreactivity by other sulfatases (40) . Therefore, the slight excess of residual ARSA activity detectable in PD extracts must be due to the small amount of genuine ARSA demonstrated with Cellogel electrophoresis, isoelectric focusing, and sucrose density gradient sedimentations (Figs. 1-3 (41) . Whether the PD individuals will show any neurological abnormality in the future remains to be seen.
ARSA in PD appeared to be structurally quite similar to that of the normal, as indicated by the similar molecular weight of about 128,000 and the heat stability with a t50 of 58. 10C (normal t5, = 57.4VC). The catalytic site also appeared to be intact because of the similar optimal pH and Km for its activity as the normal enzyme and the abolition of activity by Ag ions.
In spite of such similarities, the pI values of the ARSA in PD cells were slightly shifted towards the alkaline range (Fig. 3) 
